Understanding Gender Disparities in Disaster Preparedness: Insights from FEMA Data

Mar 01, 2025

10 likes | 100 Views

Explore gender-specific trends in disaster preparedness based on FEMA statistics. Uncover key insights to tailor disaster response efforts effectively.

Share Presentation

Embed Code

Link

fema
gender disparities
disaster preparedness
insights
data analysis
trends
response efforts

ninon

Download Presentation

Understanding Gender Disparities in Disaster Preparedness: Insights from FEMA Data

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Supplemental Figure 2 FEMALES MALES A ** ** ** ** BARNES 3 3 * ## M M B $ $ 18 M C * HPWM

- Supplemental Figure 2 -

TRANSGENIC RESEARCH The production of male-sterile wheat plants through split barnase expression is promoted by the insertion of introns and flexible peptide linkers Katja Kempe, Myroslava Rubtsova, David Riewe and Mario Gils

157 views • 1 slides

Supplemental figure 2.

Supplemental figure 2. 1 2 3 4 5 6. 1 2 3 4 5 6. 1 2 3 4 5 6. Genomic DNA. Fvg8642. Fvg12211. FvTox1. Fvg8644. Fvg13072. Fvg229. Fvg9779. Fvg13120. Fvg2963. Fvg9838. Fvg13121. Fvg9849. Fvg3084. Fvg13122. Fvg4581. Fvg10823.

101 views • 1 slides

Supplemental Figure 2

Supplemental Figure 2. A. C. B.

85 views • 1 slides

Supplemental Figure 2

Supplemental Figure 2. A).

101 views • 1 slides

Supplemental Figure 2.

MS/MS spectrum of a single peptide that identified a protein. The b and y ion series, ion scores, and ranking in the Mascot search were manually inspected. Supplemental Figure 2. Spot 6069. Spot 5331. Spot 3696. Spot 5018. Spot 4068.

222 views • 6 slides

Supplemental Figure 2

MK-1775. MK-1775 + 37.5 nM MK-8776. MK-1775 + 75 nM MK-8776. MK-1775 + 150 nM MK-8776. MK-1775 + 300 nM MK-8776. Supplemental Figure 2. A. B. HRE cells. fractional proliferation. MK-8776 ( μ M). MK-1775 ( μ M).

117 views • 1 slides

Supplemental Figure 2

Supplemental Figure 2. Supplemental Figure 2. Combined use of crizotinib or TAS-115 with erlotinib reverses resistance to EGFR-TKI induced by exogenous HGF on HCC827 cell.

172 views • 1 slides

Supplemental Figure 2

80 views • 2 slides

Supplemental Figure 2

si RNA #1. si RNA #1. si RNA #1. si RNA #1. si RNA #2. si RNA #2. si RNA #2. si RNA #2. si RNA #3. si RNA #3. si RNA #3. si RNA #3. si control. si control. si control. si control. Casp-9. Casp-2. 47kDa. 51kDa. b -actin. b -actin. Relative mRNA expression. RAIDD. PIDD.

136 views • 1 slides

Supplemental Figure 2

Supplemental Figure 2. B. A.

82 views • 1 slides

Supplemental Data Figure 2

Supplemental Data Figure 2.

90 views • 1 slides

Supplemental Figure 2

Supplemental Figure 2. EPO::miR-125b. EPOR::miR-125b.

103 views • 1 slides

Supplemental figure 2

Supplemental figure 2. WT. ARKO. B. C. ArEx2-F. ArEx4-R. loxP. loxP. wt Ar. wt AR. Exon 2. Exon 3. Exon 4. Ex3∆Ar.  -actin. Systemic DMBA treatment. Tumor detection. Ex3∆AR. Collection. Exon 4. Exon 2. A. 8. 9. 10. 11. 12. 13. 14. 15. Up to 39. Age (weeks).

108 views • 1 slides

Supplemental Figure:2

B. Fold Change. Fold Change. CREBH-N. CHOP. ATF4. sXBP1. ATF6 α -N. Fold Change. Fold Change. α - tubulin. α - tubulin. α - tubulin. Supplemental Figure:2. α - tubulin. α - tubulin. A. *. *. *. -. -. -. +. +. +. -. -. +. +. Empty vector. Empty vector. +. -. D. -.

133 views • 1 slides

Supplemental Figure 2

Supplemental Figure 2. Training Set molecules. Macrolide Antibiotics. . . . Erythromycin. Clarithromycin. . Troleandomycin. Calcium Channel Blockers. . Amlodipine. Diltiazem. . Verapamil. Nifedipine. CNS Drugs. MDE. R,S-methylenedioxymethamphetamine (MDMA). Fluoxetine.

211 views • 7 slides

Supplemental Figure 2

Molecularly defined. NKCL. Median expression.  -ENKTL. NKCL. CT( α  ) -PTCL. Median expression. CT( α  )-PTCL. NKCL.  -ENKTL. -SIGLEP3 -ITAGD -KIR2DL4 -TCR-  -KLRC3 -KLRC4 -IL34 -IL18BP -CSTW -CXCL3.  -PTCL (NHS). CT( α  ) -PTCL. -PTCL (NHS). CT( α  ) -PTCL.

128 views • 1 slides

Supplemental Figure 2

wt apaf-1 -/- p53 -/-. Pro-casp8 p48. unspecific band. ERK2. TPT (h). C 8 24 C 8 24 C 8 24. Supplemental Figure 2.

106 views • 1 slides

Supplemental figure 2

Supplemental figure 2. A. DAPI. H3K9me3. DAPI. HP1 . Parp-1 +/+ ; SirT1 +/+. Parp-1 -/- ; SirT1 +/+. B. dapi. EGFP-Parp-1. H3K9me3. a. b. c. dapi. H3K9me3. GST-Parp-1. d. e. f.

148 views • 1 slides

Supplemental Figure 2

Supplemental Figure 2. A B. Saline Saline/RT MnP MnP /RT. Saline Saline/RT MnP MnP /RT. C D. Saline Saline/RT MnP MnP /RT. Saline Saline/RT MnP MnP /RT. Supplemental Figure 2.

106 views • 3 slides

Supplemental Figure 2

Supplemental Figure 2.

93 views • 1 slides

Supplemental Figure 2

Supplemental Figure 2. a. ADP titration (Clark-type electrode). ~10.00. ~10.27. ~7.01. ~5.11. ~5.00. ~4.03. ADP titration (Seahorse XF24). b. ~3.89. ~3.10. ~2.62. ~2.03. ~1.63. c. Mitochondrial integrity test (Clark-type electrode). d.

121 views • 2 slides

Supplemental Figure 2

After CPB. Before CPB. N=17. N=18. N=17. N=18. B. A. N=17. N=18. N=17. N=18. D. C. MMP-9. MMP-9. MMP-2. MMP-2. Actin. Actin. RIPC. RIPC. Control. Control. F. E. Supplemental Figure 2.

112 views • 1 slides

More Related